Profile data is unavailable for this security.
About the company
Helix BioPharma Corp. is a clinical-stage biopharmaceutical company developing therapies in the field of immuno-oncology for the prevention and treatment of cancer based on its proprietary technological platform DOS47. The Company’s pipeline is led by Tumor Defense Breaker L-DOS47, a clinical-stage antibody-enzyme conjugate designed to prime CEACAM6-expressing tumors for increased sensitivity to therapy. L-DOS47 has completed Phase Ib studies in non-small cell lung cancer (NSCLC) and shares its CEACAM6-targeting foundation with the Company's next-generation bi-specific antibody-drug conjugates (ADCs), in discovery. The Company is also advancing two pre-IND candidates: LEUMUNA, an oral immune checkpoint modulator aimed at achieving durable remission in post-transplant leukemia relapse, and GEMCEDA, an oral gemcitabine prodrug with bioavailability on a par with IV, designed to expand treatment options for advanced cancers.
- Revenue in CAD (TTM)0.00
- Net income in CAD-4.88m
- Incorporated2008
- Employees7.00
- LocationHelix BioPharma CorpBay Adelaide Centre - North Tower 40Temperance Street, Suite 2700 TorontoTORONTO M5H 0B4CanadaCAN
- Phone+1 (604) 684-2181
- Fax+1 (905) 841-2244
- Websitehttps://www.helixbiopharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Artiva Biotherapeutics Inc | 0.00 | -107.84m | 133.70m | 106.00 | -- | 0.7598 | -- | -- | -3.25 | -3.25 | 0.00 | 5.26 | 0.00 | -- | -- | 0.00 | -42.29 | -44.57 | -45.24 | -51.09 | -- | -- | -- | -596.66 | -- | -- | 0.0006 | -- | -99.25 | -- | -127.62 | -- | 18.74 | -- |
| Cognition Therapeutics Inc | 0.00 | -38.11m | 134.64m | 25.00 | -- | 2.71 | -- | -- | -0.4816 | -0.4816 | 0.00 | 0.4138 | 0.00 | -- | -- | 0.00 | -78.86 | -59.00 | -108.44 | -75.05 | -- | -- | -- | -- | -- | -3,450.08 | 0.00 | -- | -- | -- | -31.73 | -- | -51.16 | -- |
| Actuate Therapeutics Inc | 0.00 | -32.85m | 137.06m | 10.00 | -- | 9.20 | -- | -- | -1.19 | -1.19 | 0.00 | 0.4705 | 0.00 | -- | -- | 0.00 | -150.86 | -- | -282.00 | -- | -- | -- | -- | -- | -- | -- | 0.0357 | -- | -- | -- | -10.27 | -- | -- | -- |
| Cassava Sciences Inc | 0.00 | -144.39m | 137.49m | 30.00 | -- | 1.24 | -- | -- | -2.20 | -2.20 | 0.00 | 1.69 | 0.00 | -- | -- | 0.00 | -59.99 | -28.22 | -85.37 | -29.72 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 74.96 | -- | 41.75 | -- |
| Turn Therapeutics Inc | -136.18bn | -136.18bn | 140.75m | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Helix Biopharma Corp | 0.00 | -4.88m | 141.30m | 7.00 | -- | 8.79 | -- | -- | -0.0833 | -0.0833 | 0.00 | 0.2104 | 0.00 | -- | -- | -- | -50.07 | -166.45 | -66.34 | -430.79 | -- | -- | -- | -- | -- | -24.39 | 0.0214 | -- | -- | -- | 43.81 | -- | -34.02 | -- |
| Goldenwell Biotech Inc | 85.11k | -102.31k | 141.56m | -- | -- | -- | -- | 1,663.20 | -0.0007 | -0.0007 | 0.0006 | -0.001 | 0.3126 | 0.00 | -- | -- | -37.58 | -95.49 | -41.82 | -110.12 | 100.00 | 52.18 | -120.21 | -2,064.27 | 1.16 | -4.11 | 124.14 | -- | -92.39 | -13.55 | -12.05 | -- | -- | -- |
| Korro Bio Inc | 10.04m | -120.41m | 143.25m | 87.00 | -- | 1.06 | -- | 14.27 | -9.42 | -9.42 | 0.7855 | 10.54 | 0.0364 | -- | 1.36 | 70,875.00 | -43.65 | -- | -46.92 | -- | -- | -- | -1,199.53 | -- | -- | -- | 0.00 | -- | -- | -- | -2.97 | -- | -- | -- |
| Agenus Inc | 145.48m | -48.18m | 143.72m | 316.00 | -- | -- | -- | 0.9879 | -2.09 | -2.09 | 3.94 | -8.35 | 0.4523 | -- | 286.79 | 338,066.50 | -16.63 | -58.29 | -- | -140.29 | 98.93 | 97.31 | -36.77 | -125.67 | -- | -1.17 | 6.78 | -- | -33.81 | -7.17 | 7.54 | -- | -34.16 | -- |
| Citius Oncology Inc | 0.00 | -33.72m | 146.66m | -- | -- | 2.27 | -- | -- | -0.3400 | -0.3400 | 0.00 | 0.5372 | 0.00 | -- | -- | -- | -26.72 | -- | -48.02 | -- | -- | -- | -- | -- | 0.1062 | -129.48 | 0.0781 | -- | -- | -- | -17.08 | -- | -- | -- |
| Cardiff Oncology Inc | 682.26k | -68.70m | 146.77m | 32.00 | -- | 2.20 | -- | 215.12 | -0.7976 | -0.7976 | 0.0079 | 0.7272 | 0.0079 | -- | 1.15 | 15,656.25 | -79.61 | -32.23 | -101.41 | -34.83 | -- | -- | -10,064.27 | -7,588.71 | -- | -- | 0.00 | -- | 39.96 | 22.80 | -9.62 | -- | 3.42 | -- |
| MacroGenics Inc | 173.80m | -103.34m | 147.31m | 341.00 | -- | 1.61 | -- | 0.8476 | -1.21 | -1.21 | 2.02 | 1.06 | 0.4769 | 5.23 | 3.27 | 374,266.90 | -28.36 | -33.40 | -35.18 | -40.60 | 75.41 | -- | -59.46 | -97.17 | 5.02 | -26.97 | 0.5119 | -- | 155.26 | 18.50 | -639.30 | -- | -2.88 | -- |
| Codexis Inc | 72.08m | -87.09m | 147.60m | 188.00 | -- | 2.81 | -- | 2.05 | -0.7514 | -0.7514 | 0.6238 | 0.4269 | 0.389 | 5.42 | 4.03 | 281,553.20 | -47.00 | -21.95 | -58.53 | -26.20 | 79.31 | 76.67 | -120.82 | -49.88 | 4.02 | -- | 0.5076 | -- | -15.39 | -2.82 | 14.38 | -- | 2.91 | -- |
| Immunic Inc | 0.00 | -140.33m | 149.47m | 91.00 | -- | 8.57 | -- | -- | -0.8362 | -0.8362 | 0.00 | 0.1064 | 0.00 | -- | -- | 0.00 | -195.41 | -83.24 | -396.11 | -96.02 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -7.37 | -- | 36.85 | -- |
| Coya Therapeutics Inc | 5.43m | -25.10m | 150.39m | 8.00 | -- | 2.89 | -- | 27.69 | -1.11 | -1.11 | 0.2397 | 1.63 | 0.118 | -- | -- | 498,462.50 | -54.54 | -- | -59.84 | -- | -- | -- | -462.26 | -- | -- | -- | 0.00 | -- | -40.79 | -- | -86.29 | -- | -- | -- |
| Inovio Pharmaceuticals Inc | 248.30k | -147.20m | 150.63m | 134.00 | -- | -- | -- | 606.66 | -2.63 | -2.63 | 0.0046 | -0.1441 | 0.0021 | -- | 0.1283 | 1,360.67 | -122.52 | -58.57 | -260.08 | -70.33 | -- | -- | -59,283.97 | -4,810.90 | -- | -6.49 | -- | -- | -73.83 | -44.44 | 20.62 | -- | -13.16 | -- |
Data as of Feb 12 2026. Currency figures normalised to Helix BioPharma Corp's reporting currency: Canadian Dollar CAD
